Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1 15Phase 1/2 4Phase NA 2Phase 3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 41Terminated 13Unknown 9Active not recruiting 4Recruiting 2Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 48Nasopharyngeal Carcinoma 45Neoplasms 44Multiple Myeloma 41Stomach Neoplasms 35Leukemia, Myeloid, Acute 32Ovarian Neoplasms 31Neoplasm Metastasis 31Lung Neoplasms 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Recurrence 25Small Cell Lung Carcinoma 21Brain Neoplasms 21Esophageal Neoplasms 20Colonic Neoplasms 20Uterine Cervical Neoplasms 19Lymphoma, Large B-Cell, Diffuse 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

olverembatinib 1bosutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT06423911 2025-06-03

POLARIS-2

Ascentage Pharma Group Inc.

Phase 3 Recruiting
285 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03459534 2024-10-28

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Il-Yang Pharm. Co., Ltd.

Phase 3 Recruiting
173 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡